rosacea

Topical ivermectin emerges as option for rosacea
Topical ivermectin emerges as option for rosaceaIn the search for rosacea treatments, topical ivermectin 1 percent cream met its safety endpoints in two pivotal trials that included a total of 910 actively treated subjects, Galderma announced at the 72nd Annual Meeting of the American Academy of Dermatology.
Mirvaso shows long-term efficacy for facial rednessResults of a long-term, multicenter study show that brimonidine is effective in treating moderate-to-severe facial erythema caused by rosacea.
More highlights from MauiDerm 2014New drugs, data and guidelines on acne and rosacea treatment were among the takeaways from days two and three of MauiDerm 2014. Presenters also described evidence-based suggestions for managing pigmentary disorders and updated information on infectious diseases.
Future of dermatologic innovation has bright spotsWhile government funds for research in dermatology and other medical specialties seems to be dwindling, there are forces at work that could help to pick up at least part of the slack.
Study finds evidence for rosacea subtype progression
Study finds evidence for rosacea subtype progressionA study shows data to suggest there is evidence of subtype progression in rosacea, and that flushing is not a universal characteristic of patients with subtype 1 rosacea.
Research sheds light on pathophysiology of acne, rosacea
Research sheds light on pathophysiology of acne, rosaceaAlthough the symptoms of acne and rosacea are well established, clear and definitive etiologies of these conditions have largely been unknown. Recent research, however, has shed new light into the pathophysiology of these conditions, paving the way for more targeted therapies.
Risk of rosacea higher in females with migraines
Risk of rosacea higher in females with migrainesWomen who suffer from migraines may have a slightly higher risk of rosacea, a study suggests.
FDA actions in briefRecently approved drugs
FDA approves topical rosacea drugThe Food and Drug Administration has approved Galderma’s topical gel Mirvaso (brimonidine 0.33 percent) for the treatment of facial erythema from rosacea.
VIDEO: Special considerations when treating men's skinDermatologists should consider nuances of men's skin when developing treatment plans. For example, men's skin is thicker and may require additional laser passes in some areas.